Transgene Pockets €14.4M for Anti-Cancer Combinations

Transgene has raised another €14.4M from European and US investors. The money will support the development of its pipeline.

Transgene, a biotech that develops viral-based immunotherapies, has announced that it has gained €14.4M through an oversubscribed private placement of new shares. This news comes after a number of positive results, including Transgene’s Hepatitis B vaccine succeeding at Phase I and the dosing of the first glioblastoma patient with its oncolytic virus treatment. Despite this, the company continues to struggle, with its market cap dropping by around €8M since the end of October, now worth €174M.

The funds raised will support the preclinical and clinical development of Transgene’s immunotherapies in combination with checkpoint inhibitors. The company has combined its therapeutic vaccine, TG4010, with Bristol-Myers Squibb’s nivolumab, and its Pexa-Vec oncolytic virus with nivolumab and ipilimumab. Transgene will come up against Vaximm, Merck and Pfizer’s vaccine-checkpoint inhibitor combination and BerGenBio’s combination of its AXL kinase inhibitor with Keytruda.

Image – Marian Weyo /

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.